Syndopa CR 125mg Tablet is a combination medication used to treat Parkinson’s disease, relieving symptoms such as tremors, muscle stiffness, and difficulty in movement. It should be taken consistently at the same time each day, with or without food, but high-protein meals should be avoided. Follow your doctor's prescribed dosage, and do not stop the medication abruptly without medical advice.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Levodopa is the metabolic precursor of dopamine and crosses the blood-brain barrier to be converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor that reduces the peripheral metabolism of levodopa to dopamine, thereby increasing the availability of levodopa in the brain.
Titration Following initiation, doses, and intervals may be adjusted based on therapeutic response. Typical dosing ranges from two to eight tablets per day, divided into doses every 4 to 12 hours. An interval of at least three days between dosage adjustments is recommended.
Maintenance Periodic clinical evaluations are recommended to adjust the dosage regimen. Additional antiparkinson medications like anticholinergics, dopamine agonists, and amantadine can be added.
Unsafe to consume with Syndopa CR 125.
Potentially unsafe; consult your doctor due to limited human studies but harmful animal study results.
Breastfeeding is probably safe but may cause partial or complete suppression of lactation.
It may impair ability due to dizziness, drowsiness, or double vision.
No significant dose adjustment is needed but consult your doctor.
Use with caution; dosage adjustment may be necessary.
Common side effects include dyskinesia, nausea, hallucinations, confusion, dizziness, and dry mouth. Severe side effects can include neuroleptic malignant syndrome, orthostatic hypotension, and cardiac irregularities.
Levodopa-Carbidopa prolonged-release tablets are indicated for the treatment of idiopathic Parkinson's disease, particularly to reduce "off" periods in patients who have been previously treated with levodopa/decarboxylase inhibitors or with levodopa alone and have experienced motor fluctuations.
According to current data, symptoms of Parkinson's disease are linked to dopamine depletion in the corpus striatum. Dopamine's metabolic precursor, levodopa, crosses the blood-brain barrier and is likely converted to dopamine in the brain. Carbidopa prevents peripheral levodopa from being decarboxylated.
Because carbidopa's decarboxylase inhibitory effect is limited to extracerebral tissues, combining it with levodopa increases the amount of levodopa accessible for delivery to the brain.
Dosage For patients currently treated with conventional levodopa/decarboxylase inhibitor combinations, the dosage with Levodopa-Carbidopa prolonged-release tablets should initially provide no more than approximately 10% more levodopa per day, with the dosing interval extended by 30 to 50%, ranging from 4 to 12 hours. Dosages up to 30% more levodopa per day may be necessary. Conversion guidelines from conventional to prolonged-release tablets are provided.
Administration Patients currently on levodopa alone should discontinue levodopa at least eight hours before starting the CR tablet. For those with mild to moderate disease not previously treated with levodopa, the initial dose is one CR tablet twice daily, not exceeding 600 mg of levodopa per day.
Caution is needed when administering Levodopa-Carbidopa with antihypertensive agents, antidepressants, anticholinergics, iron supplements, and other drugs that may interact with levodopa or carbidopa.
Levodopa-Carbidopa prolonged-release tablets are contraindicated in patients with hypersensitivity to any component, narrow-angle glaucoma, and those treated with non-selective monoamine oxidase inhibitors. It is also contraindicated in patients with undiagnosed skin lesions or a history of melanoma.
There is insufficient data on the use of Levodopa-Carbidopa in pregnancy. It should not be used during pregnancy or lactation.
Care is required when administering to patients with severe cardiovascular or pulmonary disease, peptic ulcer history, or convulsions. Levodopa has been associated with sleepiness and sudden sleep onset; patients must be cautious about driving or operating machinery. Behavioral monitoring is recommended due to potential impulse control disorders.
Store in a cold, dry, and light-protected location.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.